Prime Medicine, Inc. Investment Income, Interest
Prime Medicine, Inc. (PRME) reported Investment Income, Interest of $788.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-06
- Prime Medicine, Inc. investment income, interest for the quarter ending 2026-06-30 was $788.00K, a 6.06% increase year-over-year.
- Prime Medicine, Inc. investment income, interest for the quarter ending 2026-03-31 was $1.02M, a 13.62% decline year-over-year.
- Prime Medicine, Inc. investment income, interest for the quarter ending 2025-12-31 was $1.08M, a 29.58% decline year-over-year.
- Prime Medicine, Inc. investment income, interest for the quarter ending 2025-09-30 was $1.14M, a 63.70% increase year-over-year.
- Prime Medicine, Inc. investment income, interest for fiscal 2025 was $4.15M, a 17.80% increase from fiscal 2024.
- Prime Medicine, Inc. investment income, interest for fiscal 2024 was $3.52M, a 25.29% increase from fiscal 2023.
- Prime Medicine, Inc. investment income, interest for fiscal 2023 was $2.81M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $788.00K 10-Q · filed 2026-08-06 | $1.81M 10-Q · filed 2026-08-06 | $2.89M derived: sum of 3 quarters · filed 2026-08-06 | $4.03M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.02M 10-Q · filed 2026-05-07 | $2.10M derived: sum of 2 quarters · filed 2026-05-07 | $3.25M derived: sum of 3 quarters · filed 2026-05-07 | $3.99M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $2.22M derived: sum of 2 quarters · filed 2026-03-03 | $2.97M derived: sum of 3 quarters · filed 2026-08-06 | $4.15M 10-K · filed 2026-03-03 |
| 2025-09-30 | $1.14M 10-Q · filed 2025-11-07 | $1.88M derived: sum of 2 quarters · filed 2026-08-06 | $3.07M 10-Q · filed 2025-11-07 | $4.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $743.00K 10-Q · filed 2026-08-06 | $1.93M 10-Q · filed 2026-08-06 | $3.46M derived: sum of 3 quarters · filed 2026-08-06 | $4.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.18M 10-Q · filed 2026-05-07 | $2.72M derived: sum of 2 quarters · filed 2026-05-07 | $3.42M derived: sum of 3 quarters · filed 2026-05-07 | $4.03M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $2.23M derived: sum of 2 quarters · filed 2026-03-03 | $2.85M derived: sum of 3 quarters · filed 2026-03-03 | $3.52M 10-K · filed 2026-03-03 |
| 2024-09-30 | $697.00K 10-Q · filed 2025-11-07 | $1.31M derived: sum of 2 quarters · filed 2025-11-07 | $1.98M 10-Q · filed 2025-11-07 | $2.48M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $611.00K 10-Q · filed 2025-08-07 | $1.29M 10-Q · filed 2025-08-07 | $1.78M derived: sum of 3 quarters · filed 2025-08-07 | $2.19M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $676.00K 10-Q · filed 2025-05-08 | $1.17M derived: sum of 2 quarters · filed 2025-05-08 | $1.58M derived: sum of 3 quarters · filed 2025-05-08 | $2.21M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $491.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $901.00K derived: sum of 2 quarters · filed 2025-02-28 | $1.54M derived: sum of 3 quarters · filed 2025-02-28 | $2.81M 10-K · filed 2025-02-28 |
| 2023-09-30 | $410.00K 10-Q · filed 2024-11-12 | $1.04M derived: sum of 2 quarters · filed 2024-11-12 | $2.32M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $635.00K 10-Q · filed 2024-08-08 | $1.91M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |